MARKET

TBPH

TBPH

Theravance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.42
-0.30
-1.60%
After Hours: 18.42 0 0.00% 16:00 05/17 EDT
OPEN
18.60
PREV CLOSE
18.72
HIGH
18.67
LOW
17.88
VOLUME
550.21K
TURNOVER
--
52 WEEK HIGH
28.57
52 WEEK LOW
14.48
MARKET CAP
1.20B
P/E (TTM)
-4.2678
1D
5D
1M
3M
1Y
5Y
Morgan Stanley Maintains Overweight on Theravance Biopharma, Lowers Price Target to $28
Morgan Stanley maintains Theravance Biopharma (NASDAQ:TBPH) with a Overweight and lowers the price target from $30 to $28.
Benzinga · 4d ago
--Morgan Stanley Adjusts Price Target on Theravance Biopharma to $28 From $30, Maintains Overweight Rating
MT Newswires · 4d ago
Global Cyclophosphamide Market growth 2021, trend analysis, area marketplace expanding, technological innovations, business strategic, forecast to 2026
May 12, 2021 (The Expresswire) -- Global “Cyclophosphamide Market” can help you discover multiple perspectives that will help you answer your questions or...
The Express Wire · 5d ago
Chronic Idiopathic Constipation Drugs Market Business Development Strategies by Major Players 2021-2027 | Top Key Players| COVID 19 Impact Analysis
The Express Wire · 5d ago
Theravance Biopharma to Participate in an Upcoming Investor Conference
, /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in an investor event as follows:
PR Newswire - PRF · 05/06 10:00
Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track
Theravance's (TBPH) loss narrows in the first quarter of 2021 while revenues decline year over year.
Zacks · 05/05 15:45
Theravance Biopharma (TBPH) Receives a Buy from Leerink Partners
Leerink Partners analyst Geoff Porges maintained a Buy rating on Theravance Biopharma (TBPH) today and set a price target of $39.00. The company's shares
SmarterAnalyst · 05/05 12:25
Needham Maintains Buy on Theravance Biopharma, Lowers Price Target to $32
Needham analyst Joseph Stringer maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and lowers the price target from $40 to $32.
Benzinga · 05/05 11:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TBPH. Analyze the recent business situations of Theravance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TBPH stock price target is 30.38 with a high estimate of 42.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 161
Institutional Holdings: 72.35M
% Owned: 110.84%
Shares Outstanding: 65.28M
TypeInstitutionsShares
Increased
17
614.88K
New
7
109.32K
Decreased
27
538.31K
Sold Out
6
73.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.61%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Chief Executive Officer/Director
Rick Winningham
Chief Financial Officer/Senior Vice President
Andrew Hindman
Corporate Executive
Ann Brady
Executive Vice President/General Counsel/Secretary
Bradford Shafer
Senior Vice President
.. ..
Senior Vice President
Richard Graham
Senior Vice President
Frank Pasqualone
Senior Vice President
Kenneth Pitzer
Senior Vice President
Vijay Sabesan
Senior Vice President
Philip Worboys
Lead Director/Independent Director
William Young
Director
Robert Gunderson
Independent Director
Laurie Alsup
Independent Director
Eran Broshy
Independent Director
Burton Malkiel
Independent Director
Dean Mitchell
Independent Director
Susan Molineaux
Independent Director
Donal O'Connor
Independent Director
Deepika Pakianathan
Independent Director
George Whitesides
No Data
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Webull offers kinds of Theravance Biopharma Inc stock information, including NASDAQ:TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBPH stock methods without spending real money on the virtual paper trading platform.